콘텐츠로 건너뛰기
Merck
  • A Near-Infrared Probe Tracks and Treats Lung Tumor Initiating Cells by Targeting HMOX2.

A Near-Infrared Probe Tracks and Treats Lung Tumor Initiating Cells by Targeting HMOX2.

Journal of the American Chemical Society (2019-08-23)
Jong-Jin Kim, Yong-An Lee, Dongdong Su, Jungyeol Lee, Sung-Jin Park, Beomsue Kim, Jia Hui Jane Lee, Xiao Liu, Seong Soon Kim, Myung Ae Bae, Jun-Seok Lee, Seong Cheol Hong, Lu Wang, Animesh Samanta, Haw-Young Kwon, So-Young Choi, Jun-Young Kim, Young Hyun Yu, Hyung-Ho Ha, Zhenxun Wang, Wai Leong Tam, Bing Lim, Nam-Young Kang, Young-Tae Chang
초록

Tumor initiating cells (TIC) are resistant to conventional anticancer therapy and associated with metastasis and relapse in cancer. Although various TIC markers and their antibodies have been proposed, it is limited to the use of antibodies for in vivo imaging or treatment of TIC. In this study, we discovered heme oxygenase 2 (HMOX2) as a novel biomarker for TIC and developed a selective small molecule probe TiNIR (tumor initiating cell probe with near infrared). TiNIR detects and enriches the functionally active TIC in human lung tumors, and through the photoacoustic property, TiNIR also visualizes lung TIC in the patient-derived xenograft (PDX) model. Furthermore, we demonstrate that TiNIR inhibits tumor growth by blocking the function of HMOX2, resulting in significantly increased survival rates of the cancer model mice. The novel therapeutic target HMOX2 and its fluorescent ligand TiNIR will open a new path for the molecular level of lung TIC diagnosis and treatment.

MATERIALS
제품 번호
브랜드
제품 설명

Sigma-Aldrich
Retinoic acid, ≥98% (HPLC), powder
Sigma-Aldrich
BioTracker TiNIR HMOX2 Live Cell Dye
Sigma-Aldrich
Pentostatin, ≥95% (HPLC)